We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Enzo Biochem Sells Clinical Laboratory Division to Labcorp

By LabMedica International staff writers
Posted on 20 Mar 2023
Print article
Image: Enzo’s GoTestMeNow online platform allows individuals to request and pay for routine lab tests online (Photo courtesy of Enzo Clinical Labs)
Image: Enzo’s GoTestMeNow online platform allows individuals to request and pay for routine lab tests online (Photo courtesy of Enzo Clinical Labs)

Enzo Biochem (New York, NY, USA) has entered into an agreement for LabCorp Diagnostics (Burlington, NC, USA) to acquire the assets of Enzo’s Clinical Laboratory division. The deal between the two top global life sciences companies comes after several measures taken by Enzo in 2022 to further drive the company’s “focused return” initiative for maximizing shareholder value.

In 2022, Enzo Biochem had begun undertaking a strategic initiative to restructure operations to target business areas and industry sectors that offer opportunities for high growth. Enzo Life Sciences, the company’s remaining operating segment, offers a comprehensive portfolio of products and services that are vital and widely used in drug discovery, development, and translational research applications. Enzo Life Sciences’ products including antibodies, genomic probes, assays, biochemicals, and proteins are sold across the global life sciences market.

“Completion of the sale will position Enzo to assess and execute on further actions to increase shareholder value and advance our global leadership within the life sciences sector,” said Hamid Erfanian, CEO of Enzo Biochem. “We are very grateful to all our colleagues who have made Enzo Clinical Labs a trusted source for patient care. With proven expertise in clinical laboratory services and products, Labcorp is perfectly positioned to bring these operations to new levels of momentum and success.”

“Enzo Clinical Labs is renowned for high-quality testing and expert customer focus, and we look forward to integrating these capabilities through a smooth and seamless transition of services while maintaining a presence on Long Island with testing and service teams,” said Bill Haas, senior vice president of Labcorp Diagnostic’s Northeast Division. “This investment bolsters our commitment to the New York Tristate healthcare communities and we are confident that Enzo Clinical Labs patients and providers will have a combined experience that exceeds their laboratory needs.”

Related Links:
Enzo Biochem
LabCorp Diagnostics 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.